Search the Newsreel

IKT|Inhibikase Therapeutics Inc|Price:2.217|Chg%:-0.093

Inhibikase Therapeutics Inc (IKT) shows strong fundamentals and high growth potential, despite recent technical trends not fully supporting its performance. The company is considered fairly valued and has high institutional ownership. Analysts have given it a "Buy" rating with a target price indicating significant …

Sika AG (SKFOF) (H1 2026) Earnings Call Highlights: Navigating Challenges with Strategic Growth ...

This article first appeared on GuruFocus. Reported Sales: CHF5.59 billion, slight decline. Local Currency Growth: 4% for the first half of the year. Material Margin: Expanded by 60 basis points to 55.7%. EBITDA: CHF1.063 billion, flat year on year. EBITDA Margin: Expanded by 10 …

Avoiding Lag: Real-Time Signals in (ANIK) Movement

An article by Stock Traders Daily's Quantitative Research Desk suggests that Anika Therapeutics Inc. (NASDAQ: ANIK) is facing weak near and mid-term sentiment, despite a positive long-term outlook. The analysis highlights a 34.4:1 risk-reward short setup, projecting a 10.9% downside risk versus a 0.3% …

PLTK|Playtika Holding Corp|Price:3.890|Chg%:+0.210

This article provides a comprehensive stock analysis of Playtika Holding Corp (PLTK) by TradingKey, scoring its financials, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. Despite turning to a loss recently, the company shows strong fundamentals and high dividend payouts, maintaining a …

Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Inhibikase Therapeutics Inc (IKT), highlighting its current valuation score of 6.53 and its ranking within the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -5.42, which is significantly below its recent high and …

SIKA DELIVERS 4.0% LOCAL CURRENCY REVENUE GROWTH AND UPGRADES FULL-YEAR GROWTH EXPECTATIONS

Sika AG Ad Hoc Announcement Pursuant to Article 53 of the SIX Exchange Regulation Listing Rules SIKA DELIVERS 4.0% LOCAL CURRENCY REVENUE GROWTH AND UPGRADES FULL-YEAR GROWTH EXPECTATIONS Sika posts half-year sales growth of 4.0% in local currencies; reported sales of CHF 5.59 billion; …

ANIK|Anika Therapeutics Inc|Price:15.200|Chg%:+0.180

This article provides a comprehensive stock analysis of Anika Therapeutics Inc (ANIK) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership and a "Strong Buy" …

Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) by business segment and geographical region. For the fiscal year 2025, the company's revenue was primarily driven by its OEM Channel and Commercial Channel. The United States contributed the largest portion of …

Anika Therapeutics (ANIK) Proxy filing Summary

Anika Therapeutics (ANIK) recently filed a proxy summary detailing proposed changes to its 2017 Omnibus Incentive Plan, particularly Proposal 4, which faces dilution concerns despite board approval. The plan continues to use a fungible design for executive compensation, assigning higher cost to full-value awards. …

Playtika Holding Corp (PLTK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Playtika Holding Corp (PLTK), detailing regional contributions. It shows that the USA accounts for 63.22% of revenue, followed by EMEA at 23.48%, APAC at 7.40%, and other regions at 5.90%. The company has not yet disclosed detailed …

Arika Resources to Issue 344.7 Million Shares at 1.9 Cents in Placement to Fund Gold Drilling Programs

Buyback MTEL Senilai Rp35,9 Miliar Tuntas, Ini Dampaknya

Arika Resources (ASX:ARI) Strengthens Funding Position as Major Drilling Campaign Gets Underway

IKT|Inhibikase Therapeutics Inc|Price:2.330|

This article provides an analysis of Inhibikase Therapeutics Inc (IKT), highlighting its healthy fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $6.00. Despite strong stock performance and outperforming fundamentals, technical indicators suggest the stock is trading sideways, suitable …

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Inhibikase Therapeutics (Nasdaq: IKT) announced that the FDA has granted Orphan Drug Designation (ODD) to its lead product candidate IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This designation highlights the significant unmet medical need for the approximately 50,000 PAH patients in the …

Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of the dividend and stock split history for Inhibikase Therapeutics Inc (IKT). It notes that the company has not distributed any dividends in the past five years. The article also details multiple 6-to-1 merger-based stock splits that occurred on …

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen has upgraded Inhibikase Therapeutics (NASDAQ:IKT) from "strong sell" to "sell." This decision comes amidst varied analyst opinions, with some maintaining "sell" ratings while others have initiated "strong-buy" or "outperform" ratings with price targets of up to $5.00. The company's stock opened …

Playtika Holding Corp. (8II) Q1 2024 Earnings Report - Results, Call & Slides

Playtika Holding (8II) announced its Q1 2024 earnings, reporting an actual EPS of €0.12, missing the consensus of €0.14, and actual revenue of €570.57M, beating the expected revenue of €561.46M. The company's revenue saw a slight YoY decrease of 0.76%. The earnings call took …

Radhika Jeweltech appoints two independent directors for five-year term

Ambika Cotton Mills funds ₹135 crore spindle upgrade internally

Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans

Inhibikase Therapeutics announced that its lead product candidate, IKT-001, has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Pulmonary Arterial Hypertension (PAH), a condition affecting approximately 50,000 Americans. This designation provides incentives such as tax credits, exemption from FDA …

Radhika Jeweltech Share Price Forecast: 3 Year Outlook to 2030

Bikaji Foods International to Hold Q1FY27 Earnings Call on August 6

Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary

Anika Therapeutics (ANIK) presented a summary of their 2026 CG Musculoskeletal Conference, detailing their strategy to accelerate growth through commercial momentum, product pipeline advancement, and operational discipline. The company highlighted its strong financial position, robust product portfolio in OA pain management and regenerative solutions, …

Anika Therapeutics (ANIK) Expected to Post Earnings on Wednesday

Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This article is a preliminary proxy statement (PRE 14A) filed by Inhibikase Therapeutics. The document pertains to a merger or acquisition, indicating that the company is involved in a corporate transaction that requires shareholder approval or notification. The specific details of the merger or …

Tencent in talks to acquire Playtika's SuperPlay in deal worth up to $1.5 billion

Tencent is reportedly in negotiations to acquire SuperPlay, a mobile game developer, from Playtika for an estimated $1 billion to $1.5 billion. This potential sale aims to relieve Playtika of growing earnout obligations to SuperPlay's founders, which have become a significant financial burden despite …

Playtika (NASDAQ:PLTK) Shares Down 5.4% - Should You Sell?

Playtika (NASDAQ:PLTK) shares dropped 5.4% on Monday to $3.7950, with trading volume slightly above average. The company's recent earnings report showed a miss on EPS but beat revenue expectations, which increased 5.5% year over year. Analysts maintain a "Hold" consensus rating with an average …

Should Value Investors Buy Playtika (PLTK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, perhaps …

Frontier tech research, news & data

This article provides an inventory turnover analysis for Inhibikase Therapeutics, Inc. (IKT), drawing data from SEC EDGAR filings. It presents both annual and quarterly inventory turnover figures, noting that the company's inventory turnover was "—" for all listed periods, indicating a lack of activity …

Kritika Wires Share Price Forecast: 3 Year Outlook to 2030

Analysts question Indika’s Kideco divestment as coal unit remains key cash engine

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

RA Capital Management has filed an initial beneficial ownership statement (Form 3) for Inhibikase Therapeutics, declaring indirect ownership of 25 million common shares. This filing indicates RA Capital owns 10% of Inhibikase Therapeutics. The event date for the ownership was July 10, 2026, with …

Kritika Wires schedules AGM on Aug 12 to approve FY26 results

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen has downgraded Inhibikase Therapeutics (NASDAQ:IKT) from a "sell" to a "strong sell" rating. Despite this downgrade, other analysts maintain a more positive outlook, with a consensus "Buy" rating and an average price target of $5.40. The company, a clinical-stage biotech focused …

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase

RA Capital, through its Healthcare Fund, has reported a 15.9% stake in Inhibikase Therapeutics (IKT), holding 25 million shares. This ownership arose from an at-the-market offering on July 10, 2026, and the percentage is calculated based on an updated share count including these newly …